QIAstat-Dx Syndromic Testing

About Qiagen

Founded in 1984, QIAGEN has established itself as a foundational player in the life sciences tools and molecular diagnostics sector with a mission to 'make improvements in life possible.' The company's strategy is built on its integrated 'Sample to Insight' workflow solutions, serving diverse end markets from clinical diagnostics to pharmaceutical R&D. With a market cap of $8.13B and a broad portfolio, QIAGEN leverages its scale and technological breadth to drive growth in areas like digital PCR, next-generation sequencing (NGS), and syndromic testing.

Therapeutic Areas